Theramir granted US patent for treatment targeting LCP-1 positive cancers

Theramir announced that it has been granted a US Patent for its miRNA-based therapy targeted against LCP-1 positive cancers.

“This achievement reflects our relentless pursuit of innovation and our commitment to transforming the landscape of cancer treatment,” the company said announcing the news on its LinkedIn. “This patent represents not just a technical breakthrough, but a significant advancement in the fight against LCP-1 positive cancers. With miRNA-based therapeutics at its core, our approach holds immense potential to provide targeted, effective, and patient-first solutions in oncology care.”

LCP - 1 (L - Plastin, Plastin - 2, lympho cyte cytosolic protein 1) has recently been identified as a biomarker for the early detection of various forms of cancer, including kidney, colon, and breast cancer.

The document accompanying the United States Patent Application Publication said the invention relates to a novel technology using miRNAs and their ability to target and down regulate the activity of oncoproteins in LCP - 1 positive cancers. The technology designs for delivery of specific miRNA inhibitor sequences encapsulated in biological or synthetic vesicles that will affect the expression of a group of genes and proteins (including LCP1 / LCP - 1) associated with cancer initiation, growth, aggressiveness and metastasis.

So, besides the potential prognostic relevance of LCP - 1 expression and hosphorylation in human cancer cells, the treatment method is also a promising target for cancer

Therapy, while reducing LCP - 1 expression and / or phosphory lation in tumour cells may interfere with tumour cell aggressiveness, migration and invasion and, hence, reduce the chances of it spreading.Limassol-headquartered Theramir’s proprietary technologies are based on microRNAs (miRNAs), a class of small non-coding RNAs that can regulate multiple genes and pathways associated with cancer growth and metastasis.

The company has developed a panel of miRNAs, both biological and synthetic, which can affect the function and disrupt expression of an expanding list of oncoproteins that are dysregulated in most cancer types. Thus, its technologies can be applied to the development of novel targeted therapeutics that may potentially transform the precision oncology field by creating new knowledge on the pathology of the disease and by enabling the customisation and personalisation of cancer treatment.